Boulder-based SomaLogic to aid in cancer research
BOULDER — Clinical diagnostics company SomaLogic Inc. (Nasdaq: SLGC) will analyze more than 210 million protein samples to study cancer development. The Boulder-based company has announced a partnership with the European Prospective Investigation into Cancer and Nutrition to aid in cancer research.
SomaLogic’s programs will scan proteins to determine commonalities between samples gathered from more than 500,000 subjects over 20 years. SomaLogic’s chief medical officer, Stephen A. Williams, spoke about the power of protein analysis in cancer research.
“Proteomics is a powerful tool in predicting cancer because of its strengths in detecting immune surveillance and the body’s response to precancer physiology and…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
